Cefpodoxime and Potassium Clavulanate Tablets

Pacitora Biotech introduces Pacidox-CV325™, a high-strength antibiotic combination containing Cefpodoxime Proxetil 200mg and Potassium Clavulanate 125mg in a convenient oral tablet. This advanced formulation is specifically engineered for the treatment of moderate to severe bacterial infections where resistance to standard antibiotics is suspected or confirmed.

Key Benefits:

• Higher Potency – Optimized 325mg combination for moderate to severe infections.

• Beta-Lactamase Protection – Clavulanate defeats antibiotic-resistant bacteria.

• Extended Spectrum – Effective against ESBL-producing strains.

• Twice-Daily Dosing – Convenient 12-hourly regimen.

• Hospital-Grade Strength – Suitable for complicated infections.

FAQs:

1. What is the difference between Pacidox-CV and Pacidox-CV325?
Both contain the same active ingredients (Cefpodoxime 200mg + Clavulanate 125mg). Pacidox-CV325 is typically the same formulation but marketed in a larger 10×10 bulk pack for hospitals and clinics requiring higher volumes.

2. Can Pacidox-CV325 be used for children?
This 325mg tablet strength is intended for adults and children over 12 years (or weighing above 40kg). For younger children, a paediatric suspension or lower-dose tablet should be prescribed.

3. What should I do if I experience severe diarrhoea while taking this medicine?
Severe, watery, or bloody diarrhoea may indicate a C. difficile infection. Stop the medication immediately and contact your doctor – do not take anti-diarrhoeal medicines without medical advice.

4. How long does it take for Pacidox-CV325 to work?
Most patients notice symptom improvement within 48–72 hours of starting treatment. However, you must complete the entire prescribed course (usually 5–10 days) to prevent bacterial resistance and recurrence.